Last 7 days
-0.3%
Last 30 days
0.0%
Last 90 days
-3.1%
Trailing 12 Months
6.0%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 404.8B | 94.9B | -5.16% | -10.64% | 22.56 | 4.26 | 1.25% | -14.07% |
LLY | 296.8B | 28.5B | -5.67% | 20.74% | 47.53 | 10.4 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -1.75% | 40.02% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.4B | 100.3B | -8.43% | -20.95% | 7.22 | 2.26 | 23.43% | 42.74% |
BMY | 142.7B | 46.2B | -7.78% | -1.12% | 22.55 | 3.09 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.8B | 4.5B | -0.20% | -5.41% | -34.17 | 1.08 | 7.56% | -104.06% |
RETA | 3.3B | 2.2M | 105.10% | 171.03% | -10.52 | 1.5K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -9.96% | 17.66% | 31.57 | 2.87 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.74 | 2.63 | 18.18% | -18.59% |
CGC | 991.7M | 478.9M | -11.35% | -65.42% | -0.32 | 2.07 | -31.50% | -634.70% |
INVA | 792.9M | 285.2M | -7.22% | -37.95% | 3.6 | 2.78 | -27.21% | -40.28% |
CRON | 768.8M | 114.5M | -15.28% | -37.42% | -4.56 | 6.72 | 27.90% | 57.40% |
ACRS | 541.5M | 29.8M | -40.95% | -47.43% | -6.23 | 18.2 | 340.05% | 4.35% |
OCUL | 400.7M | 51.5M | -2.49% | -0.39% | -5.64 | 7.78 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -2.0% | 3,629 | 3,701 | 3,813 | 3,769 | 3,226 |
Gross Profit | -2.6% | 2,709 | 2,781 | 2,875 | 2,860 | 2,432 |
Operating Expenses | -0.6% | 2,091 | 2,104 | 2,027 | 1,963 | 1,889 |
S&GA Expenses | -1.7% | 1,541 | 1,567 | 1,530 | 1,487 | 1,446 |
R&D Expenses | -13.8% | 438 | 508 | 484 | 520 | 432 |
EBITDA | -3.8% | 1,024 | 1,064 | 1,223 | 917 | - |
EBITDA Margin | -1.9% | 0.28* | 0.29* | 0.32* | 0.24* | - |
Earnings Before Taxes | -9.7% | 527 | 584 | 756 | 807 | 463 |
EBT Margin | -7.9% | 0.15* | 0.16* | 0.20* | 0.21* | - |
Interest Expenses | 15.4% | 106 | 92.00 | 84.00 | 83.00 | 74.00 |
Net Income | -9.2% | 521 | 574 | 765 | 862 | 534 |
Net Income Margin | -7.4% | 0.14* | 0.16* | 0.20* | 0.23* | - |
Free Cahsflow | -9.1% | 1,194 | 1,314 | 1,346 | 1,182 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 1.0% | 9,115 | 9,028 | 8,853 | 8,740 | 8,678 |
Current Assets | 7.1% | 3,653 | 3,412 | 3,203 | 2,948 | 2,800 |
Cash Equivalents | 10.4% | 2,353 | 2,131 | 1,893 | 1,643 | 1,580 |
Inventory | -10.9% | 170 | 190 | 204 | 227 | 226 |
Net PPE | 7.2% | 341 | 318 | 302 | 295 | 292 |
Goodwill | 0% | 1,011 | 1,011 | 1,011 | 1,067 | 1,067 |
Current Liabilities | 10.3% | 949 | 861 | 791 | 825 | 887 |
Long Term Debt | -0.1% | 2,565 | 2,567 | 2,569 | 2,571 | - |
Shareholder's Equity | 0.8% | 5,072 | 5,034 | 4,946 | 4,818 | 4,672 |
Retained Earnings | -2.7% | 590 | 606 | 584 | 523 | 319 |
Additional Paid-In Capital | 1.1% | 4,474 | 4,425 | 4,381 | 4,315 | 4,373 |
Accumulated Depreciation | 12.7% | 54.00 | 48.00 | 42.00 | 36.00 | - |
Shares Outstanding | -0.6% | 227 | 229 | 230 | 229 | 227 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -8.2% | 1,258 | 1,370 | 1,415 | 1,255 | 1,035 |
Share Based Compensation | -2.2% | 182 | 186 | 196 | 205 | 219 |
Cashflow From Investing | -10.0% | -134 | -121 | -231 | -305 | -2,994 |
Cashflow From Financing | -96.3% | -347 | -177 | -91.16 | -109 | 1,470 |
Buy Backs | -44.9% | 250 | 454 | - | - | - |
44.6%
34.6%
12.7%
Y-axis is the maximum loss one would have experienced if Horizon Pharma was unfortunately bought at previous high price.
46.0%
32.5%
48.9%
55.6%
FIve years rolling returns for Horizon Pharma.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-13 | Crystalline Management Inc. | new | - | 5,121,000 | 5,121,000 | 2.58% |
2023-03-10 | MATHER GROUP, LLC. | new | - | 313,974 | 313,974 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 6.92 | 9,026,730 | 18,370,700 | 0.02% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 4,314 | 11,474,000 | 11,617,000 | 0.06% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | sold off | -100 | - | - | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -40.25 | 4,201,050 | 46,820,000 | 0.07% |
2023-02-24 | SRS Capital Advisors, Inc. | added | 193 | 4,349 | 5,349 | -% |
2023-02-22 | CVA Family Office, LLC | sold off | -100 | - | - | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | added | 209 | 41,276 | 49,276 | -% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -95.1 | -101,797,000 | 10,072,700 | 0.01% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.37% | 21,236,103 | SC 13G/A | |
Feb 07, 2023 | blackrock inc. | 6.5% | 14,794,254 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
Feb 03, 2022 | blackrock inc. | 5.7% | 13,008,024 | SC 13G/A | |
Feb 11, 2021 | renaissance technologies llc | 3.08% | 6,798,963 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 9.03% | 19,920,258 | SC 13G/A | |
Feb 08, 2021 | fmr llc | - | 0 | SC 13G | |
Jan 29, 2021 | blackrock inc. | 6.4% | 14,206,978 | SC 13G/A | |
Feb 12, 2020 | renaissance technologies llc | 5.39% | 10,100,675 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 69.61 -36.48% | 92.81 -15.30% | 183.90 67.82% | 308.07 181.14% | 486.84 344.28% |
Current Inflation | 63.31 -42.22% | 83.16 -24.11% | 160.90 46.83% | 265.29 142.10% | 415.39 279.07% |
Very High Inflation | 55.59 -49.27% | 71.53 -34.72% | 133.92 22.21% | 215.97 97.09% | 333.79 204.61% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 14, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 06, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 10-K | Annual Report | |
Mar 01, 2023 | 8-K | Current Report | |
Feb 24, 2023 | 8-K | Current Report | |
Feb 17, 2023 | DEFA14A | DEFA14A | |
Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
Feb 08, 2023 | DEFA14A | DEFA14A |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-13 | Thompson Elizabeth H.Z. | gifted | - | - | -2,000 | evp, research & development |
2023-03-02 | DesJardin Michael A. | acquired | 66,953 | 15.3141 | 4,372 | evp, technical operations |
2023-03-01 | Clayton Sean M. | sold (taxes) | -775,911 | 110 | -7,032 | evp, general counsel |
2023-03-01 | Clayton Sean M. | acquired | - | - | 14,129 | evp, general counsel |
2023-01-17 | SHERMAN JEFFREY W | gifted | - | - | -33,795 | evp and chief medical officer |
2023-01-17 | SHERMAN JEFFREY W | gifted | - | - | 33,795 | evp and chief medical officer |
2023-01-17 | Pasternak Andy | sold | -3,066,320 | 113 | -27,129 | evp, chief strategy officer |
2023-01-13 | Cox Aaron | sold | -4,090,850 | 113 | -36,148 | evp, chief financial officer |
2023-01-11 | SHERMAN JEFFREY W | sold | -380,921 | 113 | -3,368 | evp and chief medical officer |
2023-01-10 | SHERMAN JEFFREY W | sold | -380,752 | 113 | -3,368 | evp and chief medical officer |
Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Net sales | $ 3,629,044 | $ 3,226,410 | $ 2,200,429 |
Cost of goods sold | 920,197 | 794,512 | 532,695 |
Gross profit | 2,708,847 | 2,431,898 | 1,667,734 |
OPERATING EXPENSES: | |||
Research and development | 437,962 | 345,318 | 128,999 |
Acquired in-process research and development and milestones | 56,250 | 86,672 | 80,365 |
Selling, general and administrative | 1,541,052 | 1,446,410 | 973,227 |
Impairment of goodwill | 56,171 | ||
Impairment of long-lived asset | 12,371 | ||
Gain on sale of assets | (2,000) | (4,883) | |
Total operating expenses | 2,091,435 | 1,888,771 | 1,177,708 |
Operating income | 617,412 | 543,127 | 490,026 |
OTHER EXPENSE, NET: | |||
Interest expense, net | (83,707) | (81,063) | (59,616) |
Foreign exchange loss | (1,202) | (1,028) | (297) |
Loss on debt extinguishment | (31,856) | ||
Other (expense) income, net | (5,567) | 1,791 | 3,388 |
Total other expense, net | (90,476) | (80,300) | (88,381) |
Income before expense (benefit) for income taxes | 526,936 | 462,827 | 401,645 |
Expense (benefit) for income taxes | 5,454 | (71,664) | 11,849 |
Net income | $ 521,482 | $ 534,491 | $ 389,796 |
Net income per ordinary share—basic | $ 2.28 | $ 2.37 | $ 1.91 |
Weighted average ordinary shares outstanding—basic | 229,108,881 | 225,551,410 | 203,967,246 |
Net income per ordinary share—diluted | $ 2.22 | $ 2.27 | $ 1.81 |
Weighted average ordinary shares outstanding—diluted | 235,239,651 | 235,680,483 | 215,308,768 |
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX | |||
Interest rate swap contracts designated as cash flow hedges | $ 23,640 | ||
Pension and other post-employment benefit plan remeasurements | 4,671 | $ (13,296) | |
Foreign currency translation adjustments | (796) | (1,546) | $ 1,760 |
Other comprehensive income (loss) | 27,515 | (14,842) | 1,760 |
Comprehensive income | $ 548,997 | $ 519,649 | $ 391,556 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 2,352,833 | $ 1,580,317 |
Restricted cash | 4,755 | 3,839 |
Accounts receivable, net | 676,347 | 632,775 |
Inventories, net | 169,559 | 225,730 |
Prepaid expenses and other current assets | 449,349 | 357,106 |
Total current assets | 3,652,843 | 2,799,767 |
Property, plant and equipment, net | 340,509 | 292,298 |
Developed technology and other intangible assets, net | 2,664,777 | 2,960,118 |
In-process research and development | 810,000 | 880,000 |
Goodwill | 1,010,538 | 1,066,709 |
Deferred tax assets, net | 431,814 | 538,098 |
Other long-term assets | 204,135 | 140,738 |
Total assets | 9,114,616 | 8,677,728 |
CURRENT LIABILITIES: | ||
Accounts payable | 155,800 | 30,125 |
Accrued expenses and other current liabilities | 457,557 | 523,015 |
Accrued trade discounts and rebates | 319,780 | 317,431 |
Long-term debt—current portion | 16,000 | 16,000 |
Total current liabilities | 949,137 | 886,571 |
LONG-TERM LIABILITIES: | ||
Long-term debt, net | 2,546,837 | 2,555,233 |
Deferred tax liabilities, net | 342,017 | 390,455 |
Other long-term liabilities | 204,451 | 173,076 |
Total long-term liabilities | 3,093,305 | 3,118,764 |
COMMITMENTS AND CONTINGENCIES | ||
SHAREHOLDERS’ EQUITY: | ||
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at December 31, 2022 and December 31, 2021; 227,625,913 and 227,760,936 shares issued at December 31, 2022 and December 31, 2021, respectively; and 227,241,547 and 227,376,570 shares outstanding at December 31, 2022 and December 31, 2021, respectively | 23 | 23 |
Treasury stock, 384,366 ordinary shares at December 31, 2022 and December 31, 2021 | (4,585) | (4,585) |
Additional paid-in capital | 4,474,199 | 4,373,337 |
Accumulated other comprehensive income (loss) | 12,528 | (14,987) |
Retained earnings | 590,009 | 318,605 |
Total shareholders’ equity | 5,072,174 | 4,672,393 |
Total liabilities and shareholders' equity | $ 9,114,616 | $ 8,677,728 |